Blocking P2X7 receptor slashes neuroinflammation, opening new therapeutic avenues

Scientists at the University of Birmingham examined the P2X7 receptor’s influence on brain inflammation by treating both lab-grown microglia-like cells and neurosurgical brain slices with a specific antagonist. Blocking the receptor suppressed cytokine production, dramatically lowering inflammatory responses. The researchers also developed a technique to convert peripheral monocytes into microglia-like cells, creating a scalable model for human microglial research.

These results suggest that drugs targeting P2X7 could be repurposed for diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, traumatic brain injury, depression and schizophrenia. Lead author Nicholas Barnes emphasized the potential for clinical trials in patients who currently lack effective anti-inflammatory therapies. The findings were published in the journal Brain.